Trametinib, a MEK1/2 inhibitor, showed promise by inhibiting ERK phosphorylation, resulting in reduced proliferation of NRAS-mutated AML cells in preclinical studies [82, 83]. The gene discussed is NRAS; the disease is acute myeloid leukemia.